Ajinomoto launches low-cost glutamine product AminoStable
USA-based Ajinomoto Aminoscience, a wholly-owned subsidiary of Japan's Ajinomoto, says it has launched the stabilizing dipeptide product AminoStable (L-alanyl-L-glutamine) for use in pharmaceutical applications and cell culture research.
The compound, which is synthesized using a novel enzymatic method that produces proteins in high yield, contains glutamine. The firm says this has potential health care benefits, however, high product costs have so far limited its use.
The Raleigh, North Carolina-headquartered group added that its new production method will enable greater use of glutamine in research, as well as in the development of pharmaceutical products. The company also said that it will submit a Master Drug File to the US Food and Drug Administration in the near future.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze